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in the context of understanding fundamental hepatology, transla-
tional applications, and the challenges associated with the clinical 
qualification of novel DILI biomarkers.
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Summary: Drug-induced liver injury (DILI) accounted for > 50% 
of cases of acute liver failure and 15% of patients undergoing liver 
transplantation between 1990 and 2002. One of the biggest fears is 
unpredictable idiosyncratic drug-induced liver injury (IDILI), which 
is a major contributor to the failure of a drug to process through 
development and is a major cause of withdrawal and black box warn-
ings. Due to the low concordance of the hepatotoxicity of drugs in 
animals and humans, a fundamental understanding of the mechanis-
tic basis from novel human-relevant in vitro models and biomarkers 
is critical for the development of effective strategies to prevent and 
predict DILI.
Hepatocellular activation of drugs has been widely implicated in 
immune-mediated DILI with concomitant activation of the adaptive 
immune system. Consistent with this hypothesis, a number of HLA 
alleles that are associated with DILI have been identified. Studies with 
patient PBMC and PBMC from drug-naive donors carrying HLA risk 
alleles have shown that drugs form specific associations with HLA 
risk alleles generating T-cell antigens and hence provide the immu-
nogenetic basis for the reaction. The identification of HLA alleles as 
predisposing factors for IDILI suggests that the adaptive immune sys-
tem also participates in reactions targeting the liver. Furthermore, the 
release of damage-associated molecular pattern molecules (DAMPs), 
such as high mobility group box-1, may serve to activate cells of 
the innate immune system. Certain mediators produced by innate 
immune cells may cause liver injury, but other factors are actually 
important to promote tissue repair and regeneration. However, to 
fully define cause and effect (bioactivation vs liver failure), an inte-
grated approach based on clinical studies, in vitro experiments, and 
animal models will be required, underpinned by appropriate bio-
analysis. We have been able to characterize covalent protein adducts 
in man formed by reactive drug metabolites (nevirapine, diclofenac) 
using techniques developed for β -lactam antibiotics that associate 
with various types of drug hypersensitivity. We have also developed 
in vitro models to look at the interplay between, genetic, chemical, 
and immunologic factors using cells from both hypersensitive and 
drug-naive individuals. Such techniques and concepts should enable 
us to elucidate various mechanistic pathways and thus define both 
chemical and biological variables that underpin this rare but serious 
form of DILI.
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Summary: There is a pressing need for faster and more efficient eval-
uation of new cancer agents to improve outcomes. Although many 
of the new targeted agents have proved disappointing, there is large 
range of new agents from varying classes that need to be evaluated 
alongside a need to evaluate biomarkers to identify more responsive 
patient subgroups effectively. The current evidence on biomarkers 
that predict the response to a therapy in oncology has often arisen 
from post hoc retrospective analyses of Phase III trial data. More 
recent trials are exploring novel ways to identify potential biomarkers 
of response much earlier in the drug development process, albeit in a 
more exploratory fashion. We suggest a new approach to trial design, 
which links novel treatment evaluation with the concurrent evalua-
tion of a biomarker within a confirmatory Phase II–III trial setting.
We describe such an approach used in a new protocol in advanced 
colorectal cancer called FOCUS4. The protocol will ultimately 
answer 3 research questions for a number of treatments and bio-
markers: (1) After a period of standard first-line chemotherapy, do 
targeted novel therapies provide strong signal of activity in differ-
ent biomarker-defined populations? (2) If so, do these definitively 
improve outcomes? (3) Is evidence of activity restricted only to the 
biomarker-defined groups?
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Summary: High development cost, low development success, cost-
disciplined health care policies, and intense competition demand an 
efficient drug development process. New compounds need to bring 
value to patients by being safe, efficacious, and cost-effective com-
pared with existing treatment options.
The goal of pharmacometrics/quantitative clinical pharmacology 
(also called Modeling and Simulation) is to optimize therapies for 
adult and pediatric patients through integration, innovation, and 
impact.1
-  Quantitatively integrate multisource data and clinical, biological, 
statistical, and mathematical concepts
-  Collaborate and innovate across disciplines, enhancing scientific 
understanding and knowledge
-  Impact and enhance key decisions in drug research and development
Pharmacometric approaches, including model-based meta-analy-
ses, allow for integration and utilization of biomarker, efficacy, and 
safety data and:
-  Provide a quantitative framework for comparative efficacy/safety 
assessments of drugs
-  Create opportunities to test assumptions through “virtual” experi-
ments and optimized clinical trials
-  Facilitate research and development of new therapies for adults 
and pediatrics
A sustained collaborative effort between academia, biotech/
pharma, hospitals and scientific societies involved in research, devel-
opment, and use of medicines is required to bring pharmacometrics/
quantitative clinical pharmacology to its full potential.
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Summary: Rationale: Chocolate is a popular food. Its consumption 
is largely associated with pleasure. Beliefs on its positive impact on 
health, physical, and mental strengths have been well established for 
